News

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

Media Contact

Stephen Schultz
VP Investor Relations (U.S.)
T: 917-280-2424 / 401 500 6570
sschultz@gwpharm.com
 

Recent Press Releases

Dec 21, 2005
GW Pharmaceuticals announces that Health Canada, the Canadian regulatory authority, has issued a Qualifying Notice for the approval of Sativex®, a cannabis-based medicinal extract product.
Dec 16, 2005
During the course of this week, an inquest has taken place in Sheffield into the death of Mrs Rene Anderson. Mrs Anderson, a 69 year old diabetic, died in March 2004.
Dec 12, 2005
GW and Almirall Prodesfarma, S.A. (“Almirall”) announce that they have entered into an exclusive agreement for Almirall to market Sativex® in Europe (excluding the UK).
Nov 15, 2005
GW announces that it has been informed by the Home Office that the Drugs Minister, Paul Goggins, has confirmed that Sativex® oromucosal spray, its cannabis-based medicine, may be imported from Canada to satisfy its
Nov 09, 2005
Rheumatology, the official monthly journal of the British Society of Rheumatology (BSR), today announces the publication of the first study to use a cannabis-based medicine (CBM) for treating rheumatoid arthritis.
Nov 06, 2005
GW Pharmaceuticals is today pleased to announce that it has reached agreement with the Health Department of The Regional Government of Catalonia in Spain to supply Sativex® oromucosal spray, its cannabis-based medic
Sep 07, 2005
The cannabis based medicine, Sativex®, is effective in reducing central neuropathic pain and sleep disturbance in people with Multiple Sclerosis (MS) in a UK study published today in the medical journal, Neurology
Jun 20, 2005
GW is pleased to announce that, following the receipt of regulatory approval from Health Canada, Sativex is now available by prescription through Canadian pharmacies as an adjunctive treatment for symptomatic relief
Jun 10, 2005
In December 2004, GW announced that the Committee on Safety of Medicines (CSM), an advisory body to the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), had advised that a fur
Jun 06, 2005
In December 2004, GW announced that the Committee on Safety of Medicines (CSM), an advisory body to the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA), had advised that a fur

Pages